NasdaqGS:BEAMBiotechs
Beam Therapeutics (BEAM) Q4 Profit Surprise Challenges Bearish Earnings Narratives
Beam Therapeutics (BEAM) closed out FY 2025 with Q4 revenue of US$114.1 million and basic EPS of US$2.37, alongside net income of US$244.3 million, which sits against trailing twelve month revenue of US$139.7 million and a loss of US$80.0 million on basic EPS of US$0.81. Over recent quarters, the company has seen revenue move from US$7.5 million in Q1 2025 to US$9.7 million in Q3 2025 and then to US$114.1 million in Q4. Basic EPS shifted from losses of US$1.24, US$1.00 and US$1.10 in the...